Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non-vitamin K Antagonist Oral Anticoagulants in patients with atrial high rate episodes - an investigator-driven, prospective, randomised, double-blind, multi-centre trial initiated by the European Society of Cardiology and AFNET

Trial Profile

Non-vitamin K Antagonist Oral Anticoagulants in patients with atrial high rate episodes - an investigator-driven, prospective, randomised, double-blind, multi-centre trial initiated by the European Society of Cardiology and AFNET

Status: Discontinued
Phase of Trial: Phase III/IV

Latest Information Update: 08 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edoxaban (Primary) ; Aspirin
  • Indications Embolism; Stroke
  • Focus Therapeutic Use
  • Acronyms NOAH

Most Recent Events

  • 24 Jan 2024 This trial has been Completed in Germany, According to European Clinical Trials Database record.
  • 13 Nov 2023 Results of subanalysis of assessing the efficacy and safety of anticoagulation in patients with AHRE lasting more than 24 hour, presented at the American Heart Association Scientific Sessions 2023
  • 12 Nov 2023 Results published in the European Heart Journal

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top